PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL

Targeting B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL) has been successful with durable remissions observed with several targeted therapeutics. Protein kinase C-β (PKC-β) is immediately downstream of BCR and has been shown to be essential to CLL cell survival and proliferati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: El-Gamal, Dalia, Williams, Katie, LaFollette, Taylor D., Cannon, Matthew, Blachly, James S., Zhong, Yiming, Woyach, Jennifer A., Williams, Erich, Awan, Farrukh T., Jones, Jeffrey, Andritsos, Leslie, Maddocks, Kami, Wu, Chia-Hsien, Chen, Ching-Shih, Lehman, Amy, Zhang, Xiaoli, Lapalombella, Rosa, Byrd, John C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2014
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148770/
https://ncbi.nlm.nih.gov/pubmed/25001469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-574830
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars